- Open Access
The therapeutic efficacy of I131-PSCA-mAb in orthotopic mouse models of prostate cancer
© Yu et al.; licensee BioMed Central Ltd. 2013
- Received: 10 September 2013
- Accepted: 25 November 2013
- Published: 13 December 2013
Prostate stem cell antigen (PSCA) is upregulated in prostate cancer tissues. Here we aimed to study the therapeutic efficacy of a monoclonal antibody of PSCA-labeled I131 (I131-PSCA-mAb) in orthotopic mouse models of prostate cancer.
The proliferation, apoptosis and invasion abilities of PC-3 and LNCaP cells treated with I131-PSCA-mAb were measured by methyl thiazolyl tetrazolium assay, flow cytometry and transwell culture, respectively. The human prostate cancer models were established by orthotopic implantation of PC-3 and LNCaP cells in nude mice. I131-PSCA-mAb distribution and tumor cell apoptosis in the tumor-bearing nude mice were measured.
The inhibitory and apoptosis rates of PC-3 and LNCaP cells treated with I131-PSCA-mAb reached a maximum of 84%, 80% and 50%, 46%, respectively, which were obviously higher than in the cells treated with I131-IgG or PSCA-mAb. The invaded number of PC-3 and LNCaP cells treated with I131-PSCA-mAbe was significantly reduced (P < 0.01) compared with the control group. The ratios of I131-PSCA-mAb in tumor to intramuscular I131-PSCA-mAb (T/NT) in tumor-bearing nude mice were increased with time and reached the highest level after 8 h. T/NT stayed above 3.0 after 12 h, and the tumor could still be developed after 24 h. The number of apoptotic cells in tumor tissue of nude mice treated with I131-PSCA-mAb was larger than that in the control group.
I131-PSCA-mAb has the potential to become a new targeted therapy drug for the treatment of prostate cancer.
- Prostate cancer
- Prostate stem cell antigen
- Monoclonal antibody
- Cell apoptosis
Prostate cancer is one of the most frequently diagnosed malignancies worldwide and has become one of the leading causes of cancer-related death in men, only behind lung cancer [1, 2]. Some patients with metastatic disease die within 2–3 years of diagnosis, whereas others with organ-confined disease can live for 10–20 years, which indicates that prostate tumors might have tremendous genomic diversity .
Androgens could contribute to the initial growth of prostate cancer . In 1941, Huggins and Hodges successfully applied androgen deprivation therapy (ADT) by the injection of estrogens in metastatic prostate cancer patients in the form of surgical castration [5, 6]. Within 1–2 years after initial response, progression of prostate cancer typically occurs; ADT could be considered as the treatment of choice for patients with advanced metastatic prostate cancer [7, 8]. However, most prostate tumors ultimately progress to hormone-resistant prostate cancer (HRPC), which is androgen-independent growth, and resistance inevitably occurs within a few years, while antiandrogen therapy is initially effective . Though early detection and treatment have improved significantly, biochemical recurrence might happen to almost 40% of men after radical retropubic prostatectomy . The clinical manifestations of HRPC include increased concentrations of prostate serum antigen (PSA), bone metastases, soft-tissue/lymph node metastases and substantive pain .
Prostate stem cell antigen (PSCA) belongs to the Thy-1/Ly-6 family of the glycosylphosphatidylinositol-anchored cell membrane glycoprotein, which can overexpress in prostate cancer tissues . Although PSCA expression has been detected in all stages of prostate cancer, the increased expression level of PSCA is positively correlated with biochemical recurrence, advanced stage, transition to the castration-resistant state and metastatic progression [13–16]. Ahmad et al. reported that a plasmid-based vaccine against PSCA may have the potential to be used in multimodal treatment programs for prostate cancer . Saffran et al. found that administration of anti-PSCA mAbs could inhibit metastasis to distant sites and restrain the growth of established orthotopic tumor, which could significantly prolong the survival time of tumor-bearing mice . However, the therapeutic outcomes using anti-PSCA mAbs for prostate cancer patients are very poor and limited. There are few studies on radioimmunotherapy guided by anti-PSCA mAbs for prostate cancer. The interesting area indicating the region of interest has been used in many surveillance systems, such as medical image processing .
In this study, anti-PSCA mAbs labeled with I131 (I131-PSCA-mAb) were made to investigate the potential therapeutic efficacy of I131-PSCA-mAb for prostate cancer. The proliferation abilities, apoptosis and invasion abilities of PC-3 and LNCaP cells treated with I131-PSCA-mAb in vitro were measured by methyl thiazolyl tetrazolium (MTT) assay, flow cytometry and transwell culture, respectively. Furthermore, human prostate cancer xenograft nude mice models were established by injection of androgen-dependent LNCaP cells and androgen-independent PC-3 cells. The distribution and variation of I131-PSCA-mAb in the tumor-bearing nude mice over time were measured by single-photon emission computerized tomography (SPECT) and the ROI method. Tumor cell apoptosis was detected by the terminal-deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) technique.
Human prostate cancer PC-3 cell and LNCaP cell strains were purchased from Nanjing Keygen Biotechnology Co., Ltd. The PC-3 cells and LNCaP cells were maintained in RPMI-1640 and DMEM/F12 (GIBCO, USA) supplemented with 10% fetal calf serum (GIBCO, USA), respectively. All cells were incubated in a humidified air incubator with 5% CO2 at 37°C. The PC-3 cells and LNCaP cells at exponential growth phase were digested with 0.25% trypsin for inoculation.
All animal studies were approved by the China Ethics Committee and performed in accordance with the ethical standards. A total of 15 12-week-old male nude mice (BALB/c-nu/nu) were recruited for the study. The male nude mice were from the Model Animal Research Center of Nangjing University. The nude mice were raised under the sterile barrier system with constant temperature (25-27°C) and humidity (40-50%) as well as experimental conditions accorded with the specific pathogen-free (SPF) standard. The nude mice were freely fed with high-pressure-sterilized forage and water.
Establishment of prostate cancer models
The models of human prostate cancer were established in nude mice by orthotopic implantation. The PC-3 cells or LNCaP cells were inoculated into the anterior prostate of each nude mouse at the density of 2 × 107 cells/ml. The 15 male nude mice were randomly divided into three groups: the group inoculated with 100 μl LNCaP cells (n = 5), the group inoculated with 100 μl PC-3 cells (n = 5) and the control group inoculated with 100 μl normal saline (n = 5).
Labeling and identification of I131
The mouse anti-human PSCA IgG monoclonal antibodies (PSCA-mAb), which were specific to human orthotopic tumors in the mice and did not affect endogenous PSCA expression in these animals, were purchased from Sigma Co. in the USA. The labeling and identification of I131 in PSCA-mAb and control IgG were conducted at Shandong University.
Measurements of cell inhibitory rate, apoptosis and invasion
The PC-3 and LNCaP cells were divided into four groups treated with normal saline, I131-PSCA-mAb, I131-IgG or PSCA-mAb, respectively. The difference in proliferation ability of PC-3 and LNCaP cells treated with the above three drugs including I131-PSCA-mAb, I131-IgG and PSCA-mAb (2 ug/ul) in vitro was measured by MTT assay. Briefly, 100 μl cells with the density of 2 × 104 cells/ml was seeded into each well of a 96-well plate and incubated for 48 h. MTT (50 μl, 1 mg/ml) was added to each well, and the cells were incubated for 4 h. DMSO (150 μl) was later added to each well to solubilize the formazan crystals. The absorbance was read at 570 nm using a microplate reader. All determinations were carried out in triplicate. The inhibitory rate (IR) of the cell proliferation was calculated according to the equation: IR (%) = (1-A/A’) × 100% where A refers to the absorbance of the drug-treated group and A’ refers to the absorbance of the control group.
The difference in apoptosis of PC-3 and LNCaP cells treated with drugs in vitro was measured by an apoptosis assay kit according to the manufacturer’s instructions. AnnexinV-FITC (5 ul) was added to the cell suspension, and then propidium iodide (5 ul) was added after blending. The cells were incubated for 5–15 min at room temperature out of direct sunlight. Cell apoptosis was detected using flow cytometry (GUAVA, Millipore) within 1 h.
Cell invasion ability was determined using a transwell chamber (Corning, Mexico) with a pore size of 8.0 μm. Cells with the density of 1 × 105 cells/ml in serum-free medium were added to each insert. After being cultured for 10 h at 37°C, the cells that had invaded the membrane were fixed by 4% paraformaldehyde and stained with 0.1% crystal violet. Five fields were selected randomly from the central and surrounding membrane, and then cells in every field were counted. All determinations were carried out in triplicate.
SPECT for tumor-bearing nude mice
SPECT was performed on five tumor-bearing nude mice inoculated with androgen-independent PC-3 cells and five tumor-bearing nude mice inoculated with androgen-dependent LNCaP cells at 1 h, 4 h, 8 h, 12 h and 24 h after intravenous injection of 200 ul I131-PSCA-mAb (1 ug/ul) using a pinhole collimator. In order to block the uptake of I131 by the thyroid gland, nude mice were treated with a saturated solution of potassium iodide before the intravenous injection. The matrix was 128 × 128, and the zoom value was 1.33. The image data per frame were 2 × 105 pixels. The ratio of I131-PSCA-mAb in tumor to intramuscular I131-PSCA-mAb (T/NT) in the tumor-bearing nude mice with time was measured using the ROI method with GE Xeleris software.
Detection of tumor cell apoptosis
Apoptotic cells were detected by the TUNEL technique with an in situ cell death detection kit (Beyotime, China). The paraffin-embedded prostate tissues of the control group and experimental group were cut into 3-μm-thick sections and underwent routine deparaffinization and rehydration. Sections were incubated with the TUNEL reaction mixture containing terminal-deoxynucleotidyl transferase and label solution at 37°C for 1 h. Converted peroxidase (POD) was added later. 3, 3′-Diaminobenzidine (DAB) was used as a chromogen for final visualization.
The measurement data were expressed as mean ± standard deviation and analyzed by t-test using SPSS version 17.0 software (Chicago, IL, USA). Differences were significantly statistical at P <0.05.
Cell inhibitory rate
Cell invasion ability
SPECT for tumor-bearing nude mice
Tumor cell apoptosis
PSCA is an ideal candidate for the detection or immunotherapy of prostate cancer because it has increased expression specificity for prostate cancer and has a specific cell surface location [12, 20, 21]. Radioimmunotherapy (RIT) uses monoclonal antibodies against tumor-specific antigens in conjunction with a particle-emitting radioisotope to deliver cytocidal ionizing radiation directly to the tumor . In our study, the potential therapeutic efficacy of anti-PSCA mAbs in conjunction with I131 for prostate cancer was evaluated. We found that I131-PSCA-mAb showed great advantages in radioimmunotherapy and stronger positive anti-prostate tumor activity compared with I131-IgG and PSCA-mAb. Therefore, I131-based elimination of PSCA-producing cells seems to be a more efficient therapeutic method.
The immunotherapeutic efficacy of PSCA-mAb has been investigated by many studies considering PSCA as a putative target in a prostate cancer model, and the results of these studies have indicated that anti-PSCA antibodies have potential therapeutic roles for the treatment of prostate cancer [21, 23]. In our study, we found that PSCA-mAb could inhibit the growth, apoptosis and migration of PC-3 and LNCaP cells to some extent. Therefore, these results are consistent with previous reports on anti-PSCA-based immunotherapy. RIT, which can target the corresponding antigens via binding radionuclides to antibodies, has a promising role in the treatment of metastatic melanoma, ovarian cancer and metastatic colorectal cancer [24–26]. The characteristic and complex interactions among the tumor, host, antigen-antibody complex and radionuclide determine the effectiveness of RIT . In this study, the inhibitory and apoptosis rates of PC-3 and LNCaP cells treated with I131-PSCA-mAb reached up to the maximum of 84%, 80% and 50%, 46%, respectively, which were obviously higher than in the cells treated with I131-IgG or PSCA-mAb. Therefore, I131-PSCA-mAb could effectively inhibit the proliferation of cancer cells and promote the apoptosis of cancer cells. Compared with the control group, the number of invaded PC-3 and LNCaP cells treated with I131-PSCA-mAb was significantly reduced, which indicated that the invasion abilities of tumor cells were significantly reduced by I131-PSCA-mAb.
Furthermore, the ratios of I131-PSCA-mAb in tumor to intramuscular I131-PSCA-mAb (T/NT) in androgen-independent and -dependent tumor-bearing nude mice increased with time, which demonstrated that I131-PSCA-mAb-targeted radioimmunotherapy may have few or minimal undesired toxic effects on the other tissues. The T/NT stayed above 3.0 after 12 h, and the tumor could still be observed after 24 h. Therefore, guided treatment for prostate cancer could be precisely conducted. What is more, the number of apoptotic cells in androgen-independent or -dependent nude mice treated with I131-PSCA-mAb was larger than that in the control group. That is to say, I131-PSCA-mAb-targeted radioimmunotherapy could effectively promote cancer cell apoptosis in tumor-bearing nude mice. However, PSCA-mAb might not be able to specifically target non-PSCA-expressing tumor cells. Therefore, the applicability of I131-PSCA-mAb treatment in humans needs to be further explored.
In conclusion, I131-PSCA-mAb has the potential to become a new targeted therapy drug for the radioimmunotherapeutic treatment of prostate cancer because it exhibited good targeting ability and efficacy and few side effects in nude mice models of human prostate cancer. We optimistically anticipate that I131-PSCA-mAb can be applied in clinical therapy.
Shengqiang Yu and Fan Feng, the first two authors, should be regarded as joint first authors.
This study was supported by the Sci-tech Development Project of Shandong Province (no. 2011GGH21841).
- Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60: 277–300. 10.3322/caac.20073View ArticlePubMedGoogle Scholar
- La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, Levi F: Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol 2010, 21: 1323–1360. 10.1093/annonc/mdp530View ArticlePubMedGoogle Scholar
- Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al.: Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18: 11–22. 10.1016/j.ccr.2010.05.026PubMed CentralView ArticlePubMedGoogle Scholar
- Calcagno F, Nguyen T, Dobi E, Villanueva C, Curtit E, Kim S, Montcuquet P, Kleinclauss F, Pivot X, Thiery-Vuillemin A: Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer. Clin Med Insights Oncol 2013, 7: 1–12.PubMed CentralPubMedGoogle Scholar
- Huggins CHC: Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1: 293–297.Google Scholar
- Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002, 167: 948–951. discussion 952 10.1016/S0022-5347(02)80307-XView ArticlePubMedGoogle Scholar
- Hamberg P, Verhagen PC, De Wit R: When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Eur J Cancer 2008, 44: 1193–1197. 10.1016/j.ejca.2008.04.005View ArticlePubMedGoogle Scholar
- Sternberg CN: Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Ann Oncol 2008, 19(Suppl 7):vii91-vii95.PubMedGoogle Scholar
- Gasent Blesa JM, Godoy MP, Esparcia MF, Molla SB, Magan BM, Sempere Ortells JM, Sanchez JL: PSA response to lenalidomide therapy in a pre-treated patient with metastatic prostate cancer refractory to hormones and chemotherapy: a case report. Case Rep Oncol 2012, 5: 181–186. 10.1159/000336481PubMed CentralView ArticlePubMedGoogle Scholar
- Moul JW: Variables in predicting survival based on treating “PSA-only” relapse. Urol Oncol 2003, 21: 292–304. 10.1016/S1078-1439(03)00103-0View ArticlePubMedGoogle Scholar
- Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ: Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003, 21: 1232–1237. 10.1200/JCO.2003.06.100View ArticlePubMedGoogle Scholar
- Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, et al.: Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 1998, 95: 1735–1740. 10.1073/pnas.95.4.1735PubMed CentralView ArticlePubMedGoogle Scholar
- Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE: Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000, 19: 1288–1296. 10.1038/sj.onc.1203426View ArticlePubMedGoogle Scholar
- Han KR, Seligson DB, Liu X, Horvath S, Shintaku PI, Thomas GV, Said JW, Reiter RE: Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol 2004, 171: 1117–1121. 10.1097/01.ju.0000109982.60619.93View ArticlePubMedGoogle Scholar
- Lam JS, Yamashiro J, Shintaku IP, Vessella RL, Jenkins RB, Horvath S, Said JW, Reiter RE: Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res 2005, 11: 2591–2596. 10.1158/1078-0432.CCR-04-1842View ArticlePubMedGoogle Scholar
- Saeki N, Gu J, Yoshida T, Wu X: Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res 2010, 16: 3533–3538. 10.1158/1078-0432.CCR-09-3169PubMed CentralView ArticlePubMedGoogle Scholar
- Ahmad S, Casey G, Sweeney P, Tangney M, O’Sullivan GC: Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther 2009, 17: 1101–1108. 10.1038/mt.2009.66PubMed CentralView ArticlePubMedGoogle Scholar
- Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A: Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A 2001, 98: 2658–2663. 10.1073/pnas.051624698PubMed CentralView ArticlePubMedGoogle Scholar
- Fasquel JB, Agnus V, Moreau J, Soler L, Marescaux J: An interactive medical image segmentation system based on the optimal management of regions of interest using topological medical knowledge. Comput Meth Programs Biomed 2006, 82: 216–230. 10.1016/j.cmpb.2006.04.004View ArticleGoogle Scholar
- Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ: Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003, 30: 667–676. 10.1016/S0093-7754(03)00358-0View ArticlePubMedGoogle Scholar
- Raff AB, Gray A, Kast WM: Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett 2009, 277: 126–132. 10.1016/j.canlet.2008.08.034PubMed CentralView ArticlePubMedGoogle Scholar
- Sharkey RM, Goldenberg DM: Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006, 56: 226–243. 10.3322/canjclin.56.4.226View ArticlePubMedGoogle Scholar
- Kiessling A, Wehner R, Füssel S, Bachmann M, Wirth MP, Schmitz M: Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers 2012, 4: 193–217. 10.3390/cancers4010193PubMed CentralView ArticlePubMedGoogle Scholar
- Zalutsky MR, Pozzi OR: Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging 2004, 48: 289–296.PubMedGoogle Scholar
- Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, et al.: A phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 2003, 9: 5842–5852.PubMedGoogle Scholar
- Dadachova E, Nosanchuk JD, Shi L, Schweitzer AD, Frenkel A, Nosanchuk JS, Casadevall A: Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. Proc Natl Acad Sci U S A 2004, 101: 14865–14870. 10.1073/pnas.0406180101PubMed CentralView ArticlePubMedGoogle Scholar
- Chamarthy MR, Williams SC, Moadel RM: Radioimmunotherapy of non-Hodgkin’s lymphoma: from the ’magic bullets’ to ‘radioactive magic bullets’. Yale J Biol Med 2011, 84: 391–407.PubMed CentralPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.